Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Mar-31-23 | Dec-31-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 8-K | 8-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues: |
| Trauma and deformity | | | 72.4 | 67.8 | 65.8 | 60.6 | 58.7 | 50.0 |
| Scoliosis | | | 29.8 | 28.1 | 28.0 | 27.5 | 26.8 | 23.0 |
| Sports medicine/other | | | 4.0 | 4.1 | 4.2 | 4.1 | 3.8 | 3.2 |
| Total revenues | | | 106.2 | 100.0 | 98.0 | 92.2 | 89.3 | 76.2 |
| Revenue growth [+] | | | 19.0% | 31.3% | 37.9% | 29.6% | 28.2% | 2.6% |
| Trauma and deformity | | | 23.3% | 35.5% | 38.1% | 21.1% | 20.1% | -3.0% |
| Scoliosis | | | 11.4% | 22.2% | 35.2% | 44.8% | 41.7% | 9.7% |
| Sports medicine/other | | | 5.6% | 29.7% | 56.7% | 95.4% | 104.1% | 82.1% |
| Cost of goods sold | | | 26.1 | 24.4 | 24.6 | 21.7 | 19.8 | 17.0 |
| Gross profit | | | 80.2 | 75.6 | 73.4 | 70.4 | 69.5 | 59.1 |
| Gross margin | | | 75.5% | 75.6% | 74.9% | 76.4% | 77.9% | 77.6% |
| Selling, general and administrative [+] | | | 92.7 | 87.7 | 85.7 | 83.3 | 81.5 | 75.7 |
| Sales and marketing | | | 42.0 | 40.5 | 39.7 | 39.1 | 38.5 | 33.2 |
| General and administrative | | | 50.6 | 47.2 | 46.1 | 44.2 | 43.0 | 42.5 |
| Research and development | | | 6.7 | 6.3 | 5.5 | 6.0 | 5.8 | 5.3 |
| Other operating expenses | | | | | 0.2 | | | |
| EBITDA [+] | | | -7.5 | -7.3 | -7.3 | -15.0 | -14.2 | -19.1 |
| EBITDA growth | | | -47.1% | -61.5% | -60.8% | 51.2% | 41.3% | 237.9% |
| EBITDA margin | | | -7.1% | -7.3% | -7.5% | -16.3% | -15.9% | -25.0% |
| Depreciation and amortization | | | 11.8 | 11.1 | 10.7 | 10.2 | 9.9 | 9.2 |
| EBIT [+] | | | -19.3 | -18.4 | -18.0 | -25.2 | -24.1 | -28.2 |
| EBIT growth | | | -19.6% | -34.7% | -32.6% | 47.9% | 49.6% | 160.0% |
| EBIT margin | | | -18.2% | -18.4% | -18.4% | -27.4% | -26.9% | -37.1% |
| Interest expense | | | 2.7 | 2.1 | 2.2 | 2.5 | 2.9 | 3.8 |
| Interest expense | | | 2.7 | 2.1 | 2.2 | 2.5 | 2.9 | 3.8 |
| Other income (expense), net [+] | | | 9.2 | 4.4 | 2.9 | -4.3 | -7.0 | -7.4 |
| Change in value of contingent liability | | | -9.4 | -3.4 | -1.8 | 5.4 | 7.8 | 7.7 |
| Other | | | -0.2 | 1.0 | 1.1 | 1.1 | 0.7 | 0.2 |
| Pre-tax income | | | -12.8 | -16.1 | -17.4 | -32.0 | -34.0 | -39.4 |
| Income taxes | | | -1.3 | -1.1 | -1.1 | -1.6 | -1.3 | -1.0 |
| Tax rate | | | 10.0% | 7.0% | 6.5% | 5.0% | 3.9% | 2.6% |
| Net income | | | -11.6 | -15.0 | -16.3 | -30.3 | -32.7 | -38.4 |
| Net margin | | | -10.9% | -15.0% | -16.6% | -32.9% | -36.6% | -50.4% |
| |
| Basic EPS [+] | | | ($0.59) | ($0.78) | ($0.84) | ($1.60) | ($1.73) | ($2.08) |
| Growth | | | -65.6% | -62.6% | -54.4% | 16.5% | 26.5% | 111.4% |
| Diluted EPS [+] | | | ($0.59) | ($0.78) | ($0.84) | ($1.60) | ($1.73) | ($2.08) |
| Growth | | | -65.6% | -62.6% | -54.4% | 16.5% | 26.5% | 111.4% |
| |
| |
| Shares outstanding (basic) [+] | | | 19.4 | 19.3 | 19.3 | 19.0 | 18.9 | 18.5 |
| Growth | | | 2.7% | 4.4% | 8.3% | 12.0% | 19.6% | 22.9% |
| Shares outstanding (diluted) [+] | | | 19.4 | 19.3 | 19.3 | 19.0 | 18.9 | 18.5 |
| Growth | | | 2.7% | 4.4% | 8.3% | 12.0% | 19.6% | 22.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|